Proteasome inhibition: A novel mechanism to combat asthma

Journal of Allergy and Clinical Immunology

Volumn 104, Issue 2 I, 1999, Pages 294-300

  Elliott, Peter J ^a   Pien, Christine S ^a   McCormack, Teresa A ^a   Chapman, Ian D ^b   Adams, Julian ^a  

^a ProScript   (United States)

^b IQVIA   (United States)

Author keywords

Asthma; Cell adhesion molecules; Cytokines; Delayed type hypersensitivity; Eosinophils; Leukocytes; Nuclear transcription factor B; Proteasome; Steroids

Indexed keywords

DEXAMETHASONE; ENZYME INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LACTACYSTIN BETA LACTONE; PROTEASOME; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG EFFICACY; DRUG STRUCTURE; ENZYME INHIBITION; INTRATRACHEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE COUNT; LOEFFLER PNEUMONIA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION; TRANSCRIPTION REGULATION;

EID: 0032844108     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-6749(99)70369-6     Document Type: Article

References (71)

1. Beasley R, Roche WR, Roberts JA, Holgate ST. Cellular events in the bronchi in mild asthma and after bronchial provocation. Am Rev Respir Dis 1989;139:806-17.
2. Fleming BN, Crombie BL. Prevalence of asthma and hay fever in England and Wales. BMJ 1987;294:279-83.
3. Djukanovic R, Roche WR, Wilson JW, Beasley CR, Twentyman OP, Howarth RH, et al. Mucosal inflammation in asthma. Am Rev Respir Dis 1990;142:434-57.
4. Busse WW. Inflammation in asthma: the cornerstone of the disease and target of therapy. J Allergy Clin Immunol 1998;102:S17-22.
5. Bousquet J, Chanez P, Lacoste LY, Barneon G, Ghavanian N, Enander I, et al. Eosinophilic inflammation in asthma. N Engl J Med 1990;323:1033-9.
6. Robinson DS, Hamid Q, Ying S, Tsicopoulos A, Barkans J, Bentley AM, et al. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992;362:298-304.
7. Woolley KL, Adelroth E, Woolley MJ, Ellis R, Jordana M, O'Byrne PM. Granulocyte-macrophage colony-stimulating factor, eosinophils and eosinophil cationic protein in subjects with and without mild, stable, atopic asthma. Eur Respir J 1994;7:1576-84.
8. Montefort S, Holgate ST, Howarth PH. Leucocyte-endothelial adhesion molecules and their role in bronchial asthma and allergic rhinitis. Eur Respir J 1993;6:1044-54.
9. Owen WE, Rothenberg ME, Silberstein DS, Gasson JC, Stevens RL, Austen KF, et al. Regulation of human eosinophil viability, density, and function by granulocyte/macrophage colony-stimulating factor in the presence of 3T3 fibroblasts. J Exp Med 1987;166:129-41.
10. Rothenberg ME, Owen WE, Silberstein DS, Woods J, Soberman RJ, Austen KF, et al. Human eosinophils have prolonged survival, enhanced functional properties, and become hypodense when exposed to interleukin 3. J Clin Invest 1988;81:1986-92.
11. Smith LJ. The role of platelet-activating factor. Am Rev Respir Dis 1991;143:S100-2.
12. Page CP. Mechanisms of hyperresponsiveness: platelet-activating factor. Am Rev Respir Dis 1992;145:S31-3.
13. Drazen JM, Gaston B, Shore S. Chemical regulation of pulmonary airway tone. Ann Rev Physiol 1995;57:151-70.
14. Busse WW. The role and contribution of leukotrienes in asthma. Ann Allergy Asthma Immunol 1998;81:17-26.
15. Kita H, Ohnishi T, Okubo Y, Weiler D, Abrams JS, Gleich GJ. Granulocyte/macrophage colony-stimulating and interleukin 3 release from human peripheral blood eosinophils and neutrophils. Exp Med 1991;174:745-8.
16. Moqbel R, Hamid Q, Ying S, Barkans J, Hartnell A, Tsicopoulos A, et al. Expression of mRNA and immunoreactivity for the granulocyte/macrophage colony-stimulating factor in activated human eosinophils. J Exp Med 1991;174:749-52.
17. Drazen JM, Arm JP, Austen KF. Sorting out the cytokines of asthma. J Exp Med 1996;183:1-5.
18. Drazen JM, Israel E, O'Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 1999;340:197-206.
19. Elwood W, Lotball JO, Barnes PJ, Fan-Chung K. The effect of dexamethasone and cyclosporine A on allergen-induced airway hyperresponsiveness and inflammatory cell responses in sensitized brown Norway rats. Am Rev Respir Dis 1992;145:1289-94.
20. Chapman ED, Lee AJ, Thompson D, Templeton AGB, Milne AAY. Time course of allergen-induced leucocyte accumulation in actively sensitized Brown Norway rats [abstract]. Am J Respir Crit Care Med 1996;153:A219.
21. Chapman ID, Lee AJ, Thompson D, Gilmour L, Trotter L, Milne AAY. Allergen-induced airway hyperreactivity and eosinophil accumulation are temporally dissociated in actively sensitized brown Norway rats [abstract]. Am J Respir Crit Care Med 1997;155:A881.
22. Frigas E, Loegering DA, Gleich DJ. Cytotoxic effects of the guinea pig eosinophil major basic protein on tracheal epithelium. Lab Invest 1980;42:35-43.
23. Barnes PJ, Karin M. Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336:1066-71.
24. Baeuerle PA, Baltimore D. IκB: a specific inhibitor of the NF-κB transcription factor. Science 1988;242:540-6.
25. Matthews JR, Hay RT. Regulation of the DNA binding activity of NF-κB. Int J Cell Biol 1995;27:865-79.
26. Thanos D, Maniatis T. NF-kappa B: a lesson in family values. Cell 1995;80:529-32.
27. Baldwin AS. The NF-κB and IκB proteins: new discoveries and insights. Ann Rev Immunol 1996;16:14:649-83.
28. Schreck R, Albermann K, Baeuerle PA. Nuclear factor κB: an oxidative stress-responsive transcription factor of eukaryotic cells. Free Rad Res Commun 1992;17:221-37.
29. Chau V, Tobias JW, Bachmair A, Marriott D, Ecker DJ, Gonda DK, et al. A multiubiquitin chain is confined to specific lysine in a targeted short-lived protein. Science 1989;243:1576-83.
30. Grilli MJ, Chiu J-S, Lenardo MJ. NF-κB and rel-participants in a multiform transcriptional regulatory system. Int Rev Cytol 1993;143:1-63.
31. Goldberg AL, Stein R, Adams J. New insights into proteasome function: from archaebacteria to drug development. Chem Biol 1995;2:503-8.
32. Coux O, Tanaka K, Goldberg AL. Structure and function of the 20S and 26S proteasomes. Ann Rev Biochem 1996;65:801-47.
33. King RW, Deshaies RJ, Peters J-M, Kirschner MW. How proteolysis drives the cell cycle. Science 1996;274:1652-9.
34. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-kB1 precursor protein and the activation of NF-kB. Cell 1994;78:773-85.
35. Chen Z, Hagler J, Palombella VJ, Melandri F, Scherer D, Ballard D, et al. Signal-induced site-specific phosphorylation targets IB to the ubiquitinproteasome pathway. Genes Dev 1995;9:1586-97.
36. Barnes PJ. Nitric oxide and airway disease. Ann Med 1995;27:389-93.
37. Holgate ST, Djukanovic R, Wilson J, Roche W, Britten K, Howarth PH. Allergic inflammation and its pharmacological modulation in asthma. Int Arch Allergy Appl Immunol 1991;94:210-7.
38. Barnes PJ. Molecular mechanisms of anti-asthma therapy. Ann Med 1995;27:531-5.
39. Schimmer BP, Parker KL. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. In: Hardman JG, Limbird LE, Malinoff PB, Ruddon RW, Gilman AG, editors. Goodman and Gilman's the pharmacological basis of therapeutics. 9th ed. 1995. p. 1459-85.
40. Serafin WE. Drugs used in the treatment of asthma. In: Hardman JG, Limbird LE, Malinoff PB, Ruddon RW, Gilman AG, editors. Goodman and Gilman's the pharmacological basis of therapeutics. 9th ed. 1995. p. 659-82.
41. Saatcioglu F, Claret F-X, Karin M. Negative transcriptional regulation by nuclear receptors. Semin Cancer Biol 1994;5:347-59.
42. Omura S, Matsuzaki K, Fujimoto T, Kosuge K, Furuya T, Fujita S, et al. Lactacystin, a novel microbial metabolite, induces neuritogenesis of neuroblastoma cells. J Antibiot (Tokyo) 1991;44:113-8.
43. Fenteany G, Standaert RF, Lane WS, Choi S, Corey EJ, Schreiber SL. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science 1995;268:726-31.
44. Dick LR, Cruikshank AA, Grenier L, Melandri FD, Nunes SL, Stein RL. Mechanistic studies on the inactivation of the proteasome by lactacystin. J Biol Chem 1996;271:7273-6.
45. Dick LR, Cruikshank AA, Destree AT, Grenier L, McCormack TA, Melandri FD, et al. Mechanistic studies on the inactivation of the proteasome by lactacystin in cultured cells. J Biol Chem 1997;272:182-8.
46. Soucy F, Plamondon L, Behnke M, Roush W. Synthesis of clasto-lactacystin β-lactone and analogs thereof. 1999. USA Application No. 60/055,848.
47. Barnes PJ, Adcock IM. NF-κB: a pivotal role in asthma and a new target for therapy. Trends Pharmacol Sci 1997;18:46-50.
48. Stein RL, Melandri F, Dick L. Kinetic characterization of the chymotryptic activity of the 20S proteasome. Biochem 1996;35:3899-908.
49. Thorne PS, Hawk C, Kaliszewski SD, Guiney PD. The noninvasive mouse ear swelling assay. Fundam Appl Toxicol 1991;17:790-806.
50. Cannon WC, Blanton EF, McDonald KE. The flow past chamber: an improved nose only exposure system for rodents. Am Indust Hyg Assoc J 1983;44:923-8.
51. Van Loveren H, Meade R, Askenase PW. An early component of delayed-type hypersensitivity mediated by T cells and mast cells. J Exp Med 1983;157:1604-17.
52. Asherson GL, Ptak W. Contact and delayed hypersensitivity in the mouse. I. Active sensitization and passive transfer. Immunology 1968;15:405-16.
53. Phanuphak P, Moorhead JW, Claman HN. Tolerance and contact sensitivity to DNFB in mice. I. In vivo detection by ear swelling and correlation with in vitro cell stimulation. J Immunol 1974;112:115-23.
54. Claman HN, Miller SD. Immunoregulation of contact sensitivity. J Invest Dermatol 1980;74:263-6.
55. Cobb RR, Felts KA, Parry GCN, Mackman N. Proteasome inhibitors block VCAM-1 and ICAM-1 gene expression in endothelial cells without affecting nuclear translocation of nuclear factor-κB. Eur J Immunol 1996;26:839-45.
56. Butcher EC. Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell 1991;67:1033-6.
57. Katz AM, Rosenthal D, Sauder DN. Cell adhesion molecules: structure, function, and implication in a variety of cutaneous and other pathologic conditions. Int J Dermatol 1991;30:153-60.
58. Picker LJ, Butcher EC. Physiological and molecular mechanisms of lymphocyte homing. Ann Rev Immunol 1992;10:561-91.
59. Palombella VJ, Conner EM, Fuseler JW, Destree A, Davis JM, Laroux FS, et al. Role of the proteasome and NF-κB in streptococcal cell wall-induced polyarthritis. Proc Natl Acad Sci 1998;95:15671-6.
60. Teelucksingh S, Padfield PL, Tibi L, Gough KJ, Holt PR. Inhaled corticosteroids, bone formation, and osteocalcin. Lancet 1991;33:60-1.
61. Geddes DM. Inhaled corticosteroids: benefits and risks. Thorax 1992;47:404-7.
62. Ray A, LaForge S, Sehgal PB. On the mechanism for efficient repression of the interleukin-6 promoter by glucocorticoids: enhancer, TATA box, and RNA start site (Inr motif) occlusion. Mol Cell Biol 1990;10:5736-46.
63. Mukaida N, Morita M, Ishikawa Y, Rice N, Okamoto S-I, Kasahara T, et al. Novel mechanism of glucocorticoid-mediated gene repression. J Biol Chem 1994;269:13289-95.
64. Chomczynski P, Qasba P, Topper YJ. Transcriptional and post-transcriptional roles of glucocorticoid in the expression of the rat 25,000 molecular weight casein gene. Biochem Biophys Res Commun 1986;134:812-8.
65. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-κB activity through induction of IκB synthesis. Science 1995;270:286-90.
66. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS. Role of transcriptional activation of IκBα in mediation of immunosuppression by glucocorticoids. Science 1995;270:283-6.
67. Hass R, Brach M, Gunji H, Kharbanda S, Kufe D. Inhibition of EGR-1 and NF-κB gene expression by dexamethasone during phorbol ester-induced human monocytic differentiation. Biochem Pharmacol 1992;44:1569-76.
68. Ray A, Prefontaine KE. Physical association and functional antagonism between the p65 subunit of transcription factor NF-κB and the glucocorticoid receptor. Proc Natl Acad Sci 1994;91:752-6.
69. Scheinman RI, Gualberto A, Jewell CM, Cidlowski JA, Baldwin AS. Characterization of mechanism involved in transrepression of NF-κB by activated glucocorticoid receptors. Mol Cell Biol 1995;15:943-53.
70. Unlap T, Jope RS. Inhibition of NFκB DNA binding activity by glucocorticoids in rat brain. Neurosci Lett 1995;198:41-4.
71. Pates PC, Ledger PW, Aston R. Recent advances in the treatment of septic shock. Expert Opinion in Therapeutic Patents 1994;4:917-30.